199 related articles for article (PubMed ID: 29579692)
1. Prostate-specific antigen (PSA) as a possible biomarker in non-prostatic cancer: A review.
Pérez-Ibave DC; Burciaga-Flores CH; Elizondo-Riojas MÁ
Cancer Epidemiol; 2018 Jun; 54():48-55. PubMed ID: 29579692
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers for prostate cancer detection.
Reed AB; Parekh DJ
Expert Rev Anticancer Ther; 2010 Jan; 10(1):103-14. PubMed ID: 20014890
[TBL] [Abstract][Full Text] [Related]
3. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening.
Catalona WJ; Smith DS; Wolfert RL; Wang TJ; Rittenhouse HG; Ratliff TL; Nadler RB
JAMA; 1995 Oct; 274(15):1214-20. PubMed ID: 7563511
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen screening: pro.
Loeb S; Catalona WJ
Curr Opin Urol; 2010 May; 20(3):185-8. PubMed ID: 20224413
[TBL] [Abstract][Full Text] [Related]
6. [Circulating prostatic-specific antigen in benign hypertrophy and localized prostate cancer: can PSA be considered a screening examination for localized cancer?].
Perrin P; Francois O; Maquet JH; Bringeon G; Duteil P; Devonec M
Prog Urol; 1991 Jun; 1(3):419-31. PubMed ID: 1726943
[TBL] [Abstract][Full Text] [Related]
7. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
Mikolajczyk SD; Rittenhouse HG
Rinsho Byori; 2004 Mar; 52(3):223-30. PubMed ID: 15137320
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.
Catalona WJ; Smith DS; Ornstein DK
JAMA; 1997 May; 277(18):1452-5. PubMed ID: 9145717
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen.
Ornstein DK; Pruthi RS
Expert Opin Pharmacother; 2000 Dec; 1(7):1399-411. PubMed ID: 11249473
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen: current status.
Lukes M; Urban M; Záleský M; Zachoval R; Herácek J; Zdárský E
Folia Biol (Praha); 2001; 47(2):41-9. PubMed ID: 11321246
[TBL] [Abstract][Full Text] [Related]
11. [New challenges and earlier approved methods in the laboratory diagnosis of prostate cancer].
Kovács GL
Magy Onkol; 2014 Dec; 58(4):301-9. PubMed ID: 25517448
[TBL] [Abstract][Full Text] [Related]
12. Investigation on core-fucosylated prostate-specific antigen as a refined biomarker for differentiation of benign prostate hyperplasia and prostate cancer of different aggressiveness.
Lang R; Rolny V; Leinenbach A; Karl J; Swiatek-de Lange M; Kobold U; Schrader M; Krause H; Mueller M; Vogeser M
Tumour Biol; 2019 Mar; 41(3):1010428319827223. PubMed ID: 30907281
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen kinetics in localized and advanced prostate cancer.
Fitzpatrick JM; Banu E; Oudard S
BJU Int; 2009 Mar; 103(5):578-87. PubMed ID: 19210674
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen testing across the spectrum of prostate cancer.
Haythorn MR; Ablin RJ
Biomark Med; 2011 Aug; 5(4):515-26. PubMed ID: 21861672
[TBL] [Abstract][Full Text] [Related]
15. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
[TBL] [Abstract][Full Text] [Related]
16. PSA testing: an evolving relationship with prostate cancer screening.
Constantinou J; Feneley MR
Prostate Cancer Prostatic Dis; 2006; 9(1):6-13. PubMed ID: 16314892
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer screening.
Sikaris K
Pathology; 2012 Feb; 44(2):99-109. PubMed ID: 22198258
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer screening by prostate-specific antigen (PSA); a relevant approach for the small population of the Cayman Islands.
Jyoti SK; Blacke C; Patil P; Amblihalli VP; Nicholson A
Cancer Causes Control; 2018 Jan; 29(1):87-92. PubMed ID: 28918559
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic significance of prostate specific antigen and the development of a mass screening system for prostate cancer.
Imai K; Ichinose Y; Kubota Y; Yamanaka H; Sato J
J Urol; 1995 Sep; 154(3):1085-9. PubMed ID: 7543604
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen assay using whole blood samples spotted on filter paper and its application to mass screening for prostate cancer.
Nanri M; Nanri K; Fujiyama C; Tokuda Y; Nakamura K; Uozumi J
Int J Urol; 2007 Jun; 14(6):505-9. PubMed ID: 17593094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
